Ads
related to: cll latest developments in treatment- CLL/SLL Efficacy Data
Find Data From Clinical
Trials Of A CLL/SLL Treatment
- CLL/SLL Dosing Guidelines
Get Dosing & Prescribing Info
For A CLL Treatment.
- Educational Materials
Find A Selection Of Resources To
Help Your Patients With CLL
- Patient Support Program
Offers Information & Resources Your
Patients May Need During Treatment.
- Mechanism Of Action
Learn More About Treatment-Related
Lymphocytosis In A CLL Trial
- CLL/SLL Safety Data
Find Important Safety
Information Of A CLL/SLL Treatment
- CLL/SLL Efficacy Data
Search results
Results From The WOW.Com Content Network
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. [8] [9] In CLL, the bone marrow makes too many lymphocytes, which are a type of white blood cell. [8] [9] Many people do not have any symptoms when they are first diagnosed. [8] [2] Those with symptoms may experience fevers, fatigue, night sweats, and ...
Idelalisib (trade name Zydelig; codenamed CAL-101, GS-1101; PIK3CD inhibitor): FDA-approved in July 2014 for treatment of three types of blood cancers: treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in combination with rituximab, treatment of relapsed small lymphocytic lymphoma after at least two prior systemic therapies, and treatment of follicular lymphoma (FL) after ...
Idelalisib is a second-line medication for people whose chronic lymphocytic leukemia (CLL) has relapsed. Used in combination with rituximab, [9] idelalisib is to be used in people for whom rituximab alone would be considered appropriate therapy due to other existing medical conditions. [9]
In May 2016, a new indication for ibrutinib was approved in the United States for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). [31] In January 2017, a new indication for ibrutinib was approved in the United States for the treatment of adults with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require ...
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. [8] In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. [8] It is given by injection into a vein. [8]
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
Ads
related to: cll latest developments in treatment